November 30 - December 1, 2022
Digital Conference8:00AM EST // 1:00PM GMT // 2:00PM CETKey Sessions
Gunnel Hallden
Panel: Combination vs. Monotherapy: The Way Forward for Oncolytic Viruses
AstraZeneca, UK
Richard Vile
Targeting Solid Tumors Using Oncolytic Virus and CAR T Cell Combined Therapy
Mayo Clinic, USA
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Day 1 - Oncolytic Viruses - November 30th - ET (Eastern Time, GMT-05:00)
keyboard_arrow_leftSearch & Filter
search
Topics
Day 1 - Oncolytic Viruses - November 30th - ET (Eastern Time, GMT-05:00)
search
Topics
Showing 1 of 1 Streams
Oncolytic Viruses/Non-Viral Gene Therapy
8:00am - 8:05am
Welcoming Remarks
- Lottie Leinfellner - Digital Events Conference Producer, Informa Connect, UK
8:05am - 8:35am
Advances in the Field of Oncolytic Viruses and Future Outlooks
- Samuel Rabkin - Thomas A Pappas Professor in Neuroscience, Harvard Medical School, USA
8:35am - 9:05am
Armed Vesicular Stomatitis Virus for the Modulation of Pancreatic Tumor Microenvironment
- Ming Luo - Professor, Georgia State University, USA
9:05am - 9:35am
The Codon-Modified Virotherapeutic CodaLytic™ Modulates the Tumor Microenvironment in Models with Different Immune Contextures
- Johanna Kaufmann - Executive Vice President for Oncology, Codagenix Inc., USA
9:35am - 9:50am
Coffee break & Networking
9:50am - 10:20am
A Novel Oncolytic Virotherapy, VET3-TGI, Displays Potent Therapeutic Activity in Multiple Mouse Tumor Models through Blocking TGF-beta and Augmenting Type-1 Immune Response
- Steve Thorne - CSO, KaliVir Immnuotherapeutics, USA
10:20am - 10:50am
Next-Generation Retroviral Replicating Vector Systems: Perspectives and Potential
- Noriyuki Kasahara - Professor, University of California San Francisco, USA
10:50am - 11:20am
An Unexpected Synergisms of YB-1 Based Oncolytic Adenovirus in Combination with CDK 4/6- and Bromodomain Inhibition
- Per Sonne Holm - University Professor, Department of Oral and Maxillofacial Surgery, Medical University Innsbruck, Austria
11:20am - 11:50am
Emerging Results with a Cytokine Armed Oncolytic Adenovirus Designed to Enable T-cell Responses
- Victor Cervera-Carrascón - Vice President of Business Development, TILT Biotherapeutics, Finland
11:50am - 12:05pm
Coffee break & Networking
12:05pm - 12:35pm
Panel: Combination vs. Monotherapy: The Way Forward for Oncolytic Viruses
- Gunnel Hallden - Director, Oncolytic Virotherapy, AstraZeneca, UK
- Howard Kaufman - Lecturer, Harvard Medical School, USA
- Abhisek Mitra - Senior Scientist Team Lead, AstraZeneca, USA
12:35pm - 1:05pm
Targeting the CD40 and 4-1BB Pathways Using LOAd703 Virotherapy
- Angelica Loskog - Professor of Immunotherapy & Chief Executive Officer/Chief Scientific Officer, Uppsala University & Lokon Pharma AB, Sweden
1:05pm - 1:35pm
CG0070: E2F Driven GM-CSF Encoding Oncolytic Virus for Bladder Cancer
- James Burke - Chief Medical Officer, CG Oncology, USA
1:35pm - 2:05pm
Targeting Solid Tumors Using Oncolytic Virus and CAR T Cell Combined Therapy
- Richard Vile - Consultant, Department of Molecular Medicine, Mayo Clinic, USA
2:05pm - 2:35pm
Learning All We Can from Translational Analysis of Samples from Patients in Oncolytic Virotherapy Trials
- Alan Melcher - Team Leader, Centre for Translational Immunotherapy, The Institute of Cancer Research, UK
2:35pm - 3:05pm
Exosome Therapeutics: Enabling Broader Application of Genetic Medicines
- Tony De Fougerolles - CEO, Evox Therapeutics Limited
Filter
Topics